Biochemical premotor biomarkers for Parkinson's disease

被引：28

作者：

Mollenhauer, Brit ^{[1
,2
]}

Zhang, Jing ^{[3
]}

机构：

[1] Paracelsus Elena Klin, D-34128 Kassel, Germany

[2] Univ Gottingen, Kassel, Germany

[3] Univ Washington, Dept Pathol, Seattle, WA 98195 USA

来源：

MOVEMENT DISORDERS | 2012年 / 27卷 / 05期

关键词：

biomarkers; genomics; metabolomics; Parkinson's disease; premotor; proteomics; HUMAN CEREBROSPINAL-FLUID; ALPHA-SYNUCLEIN; GENE-EXPRESSION; URIC-ACID; ALZHEIMER; PROTEIN; URATE; DJ-1; CSF; PROTEOMICS;

D O I：

10.1002/mds.24956

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

A biomarker is a biological characteristic that is objectively measured and evaluated as an indicator of normal biological or pathologic processes or of pharmacologic responses to a therapeutic intervention. We reviewed the current status of target protein biomarkers (eg, total/oligomeric a-synuclein and DJ-1) in cerebrospinal fluid, as well as on unbiased processes that can be used to discover novel biomarkers. We have also provide ddetails about strategies toward potential populations/models and technologies, including the need for standardized sampling techniques, to pursue the identification of new biochemical markers in the premotor stage of Parkinson's disease in the future. (C) 2012 Movement Disorder Society

引用

页码：644 / 650

页数：7

共 50 条

[41] Parkinson’s disease risk score: moving to a premotor diagnosis
Jürgen Winkler
Reinhard Ehret
Thomas Büttner
Ulrich Dillmann
Wolfgang Fogel
Michael Sabolek
Juliane Winkelmann
Jan Kassubek
Journal of Neurology, 2011, 258 : 311 - 315
[42] Defining premotor Parkinson's disease: a window of opportunity for neuroprotection?
Mahlknecht, Philipp
Poewe, Werner
NEURODEGENERATIVE DISEASE MANAGEMENT, 2013, 3 (01) : 61 - 70
[43] Parkinson's disease: premotor clinico-pathological correlations
Wolters, E. Ch.
Braak, H.
JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 2006, (70): : 309 - 319
[44] Premotor Parkinson's Disease: Clinical Features and Detection Strategies
Stephenson, Randolph
Siderowf, Andrew
Stern, Matthew B.
MOVEMENT DISORDERS, 2009, 24 (14) : S665 - S670
[45] Diagnosis of Parkinson's disease in the premotor phase. Is it ethical to 'seek' a diagnosis in the premotor phase?
Linazasoro-Cristobal, Gurutz
REVISTA DE NEUROLOGIA, 2010, 50 : S7 - S7
[46] Biomarkers for Alzheimer's disease and Parkinson's disease
Growdon, John H.
Irizarry, Michael C.
Scherzer, Clemens
ADVANCES IN ALZHEIMER'S AND PARKINSON'S DISEASE: INSIGHTS, PROGRESS, AND PERSPECTIVES, 2008, 57 : 169 - 174
[47] Biomarkers in Huntington's and Parkinson's Disease
O'Keeffe, Grainne C.
Michell, Andrew W.
Barker, Roger A.
BIOMARKERS IN BRAIN DISEASE, 2009, 1180 : 97 - 110
[48] MicroRNAs as Biomarkers for Parkinson's Disease
Bissonnette, S.
Thomas, C.
Labadorf, A.
James, R.
Saint-Hilaire, M.
Myers, R.
MOVEMENT DISORDERS, 2018, 33 : S629 - S629
[49] Candidate biomarkers for Parkinson's disease
Khodadadian, Ali
Hemmati-Dinarvand, Mohsen
Kalantary-Charvadeh, Ashkan
Ghobadi, Amin
Mazaheri, Mahta
BIOMEDICINE & PHARMACOTHERAPY, 2018, 104 : 699 - 704
[50] Biomarkers of Parkinson's Disease: An Introduction
Titova, Nataliya
Qamar, Mubasher A.
Chaudhuri, K. Ray
PARKINSON'S DISEASE, 2017, 132 : 183 - 196

← 1 2 3 4 5 →